Homotaurina

Homotaurine (Tramiprosate / 3-APS): A Comprehensive Reference

1. Identity and Chemistry

Chemical Names and Nomenclature

Homotaurine, chemically known as 3-aminopropane-1-sulfonic acid, is an organic compound with the molecular formula C₃H₉NO₃S and a molecular weight of 139.17 g/mol. It features a linear structure consisting of an amino group (−NH₂) at one end and a sulfonic acid group (−SO₃H) at the other, connected by a three-carbon propane chain (H₂N−(CH₂)₃−SO₃H), making it a structural analog of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) and the amino acid taurine, from which it derives its name as the homolog with an additional methylene group.

Homotaurine is also known as tramiprosate (INN), 3-amino-1-propanesulfonic acid, or 3-APS, and is a natural sulfonic acid found in seaweed. In pharmaceutical development contexts it has been marketed under the brand names Alzhemed™ (for Alzheimer's disease research) and Vivimind™ (as a dietary supplement). Its N-acetylated derivative, acamprosate (calcium acetylhomotaurine), is a related pharmaceutical molecule. Acamprosate (calcium acetylhomotaurine) is derived from homotaurine, a nonspecific γ-aminobutyric acid (GABA) agonist.

Natural Sources

Homotaurine, a sulfonic acid and structural homolog of taurine, occurs naturally in various marine red algae, serving as a primary biological source. Homotaurine (HT) is structurally closely related to taurine, having an additional carbon in its backbone. While abundant in seaweed, HT has not been reported in vertebrates.

Specific algal species confirmed to contain homotaurine include: Gratelupia livida, Chondrus ocellatus, Rhodymenia intricata, Acrosorium uncinatum, and Cladophora densa. Homotaurine has been extracted from dry leaves of the seaweed dulse (Rhodymenia palmata (Linnaeus) Greville) and also from a powdered dulse preparation currently marketed in the United States as an herbal dietary supplement. The seaweed-extracted homotaurine has been characterized by comparison with synthesized homotaurine using LC-MS and ¹H-NMR analyses, and the two have been determined to be chemically identical.

The United States Food and Drug Administration (US FDA) has listed Rhodymenia palmata (L.) Grev. under subchapter A of the Generally Recognized as Safe (GRAS) regulations (21 CFR 582.30 and 21 CFR 582.40) as a natural substance or extractive to be used in conjunction with spices and other natural seasonings and flavorings.

Commercial Forms and Preparations

Homotaurine is an amino acid found in some seaweeds; however, commercial products sold as supplements are made in a laboratory. The compound is available as oral capsules and tablets. After the failure of phase 3 clinical trials, homotaurine began to be sold as a supplement called Vivimind; however, in 2011 the FDA refused to permit sales of Vivimind in the US because, while homotaurine is naturally found in seaweed, the homotaurine in Vivimind was made synthetically.

A prodrug of homotaurine known as ALZ-801 (valiltramiprosate) has been developed for clinical investigational use. ALZ-801 (Valiltramiprosate) is a valine-conjugated form of homotaurine and an oral prodrug hydrolyzed into valine and homotaurine in the body. ALZ-801 is an orally administered tramiprosate prodrug with significantly improved pharmacokinetic variability and gastrointestinal tolerance.

2. Traditional and Historical Use

Homotaurine as an isolated compound has no independent history of traditional or pre-modern medicinal use. Its occurrence as a trace constituent within red seaweeds, however, connects it indirectly to long-standing ethnobotanical food traditions. Red algae such as Palmaria palmata (dulse) and Porphyra species (laver/nori/gim) are a traditional part of European and Asian cuisines and are used to make products such as agar, carrageenans, and other food additives.

Palmaria palmata is popular in coastal communities of the North Atlantic, particularly Ireland, Scotland, Iceland, Norway, France, and Eastern Canada. Rhodymenia palmata is often served whole as a salty snack, as an herb seasoning for cooking, or ground into flakes or powder. It is often used in place of tortilla chips in nachos or other dishes and can be incorporated into soups, salads, chowders, and bread dough. In Russia, this seaweed is fermented into an alcoholic beverage.

Seaweeds are widespread and traditionally used in Eastern countries for food and for medicinal purposes. The identification of homotaurine as a discrete bioactive molecule present within these edible algae is a product of modern analytical chemistry; Miyazawa et al. (1970) isolated homotaurine along with taurine and 2-hydroxyhomotaurine from Gratelupia livida, which had been collected from the intertidal zone, and confirmed identity by elemental analysis and infra-red spectra (IR). This 1970 report is credited as the first identification of homotaurine of biological origin in marine algae.

There are no documented records of homotaurine-specific preparations being intentionally produced or administered in any traditional medicine system. Its pharmacological investigation is entirely a product of late twentieth- and twenty-first-century scientific research.

3. Key Constituents, Chemical Relationships, and Active Compounds

Structural Relationships

Homotaurine is analogous to taurine, but with an extra carbon in its chain. It has GABAergic activity, apparently by mimicking GABA, which it resembles. Homotaurine and taurine are structural GABA analogs with close structural similarities with GABA. This three-way structural family—GABA, taurine, homotaurine—underpins the compound's pharmacological activity across multiple receptor systems.

Primary Metabolite: 3-Sulfopropanoic Acid (3-SPA)

The primary metabolite of homotaurine (and its prodrug ALZ-801) is 3-sulfopropanoic acid (3-SPA), an endogenous molecule in the human brain that is present in the cerebrospinal fluid (CSF) of patients with Alzheimer's disease and other neurodegenerative conditions. 3-SPA is an endogenous molecule present in the brain of patients with AD and other neurodegenerative disorders and has demonstrated anti-Aβ aggregation activity in vitro, with an efficacy comparable to tramiprosate. Thus, clinical improvements observed with tramiprosate or ALZ-801 may be partially due to the potential protective role of 3-SPA in the brain.

Acamprosate: A Related Derivative

Acamprosate (calcium acetyl-homotaurine) is a synthetic compound that crosses the blood-brain barrier and has a chemical structure similar to that of the naturally occurring amino acid neuromediators, homotaurine and γ-aminobutyric acid (GABA). Acamprosate (calcium acetylhomotaurine) is derived from homotaurine, a nonspecific GABA agonist. The molecule is N-acetylated to facilitate penetration across the blood–brain barrier, and is formulated as a calcium salt to increase absorption of the compound.

4. Mechanisms of Action

4.1 Anti-Amyloid / Anti-Aggregation Activity

Homotaurine's mechanism of action involves reducing amyloid-beta (Aβ) aggregation, thereby mitigating Alzheimer's disease and mild cognitive impairment. It stabilizes Aβ monomers, inhibits oligomer formation, and reduces Aβ42 levels in the cerebrospinal fluid.

Tramiprosate was originally found to maintain Aβ in a non-fibrillary, soluble form, resulting in inhibition of neuronal toxicity. In recent studies, tramiprosate and its active metabolite 3-sulfopropanoic acid (3-SPA) were shown to interact with soluble Aβ monomers to prevent amyloid aggregation by blocking monomeric assembly, thus preventing the formation of soluble toxic oligomer intermediates, from dimers to decamers.

It was reported that HT prevented Aβ aggregation and amyloid formation; it was observed that 100 μM HT prevented a structural shift of Aβ40 from random coil to β-sheet. In preclinical studies, tramiprosate reduced oligomer formation and fibrillar (plaque) amyloid deposition in mouse models of AD. Treatment with tramiprosate induced a decrease of soluble amyloid protein levels and its deposition in the brain (plaque). Also, plasma Aβ levels declined in a dose-dependent manner, indicating a role of tramiprosate in brain metabolism of Aβ or in its transport.

In vivo, chronic oral tramiprosate treatment of TgCRND8 mice resulted in a significant reduction (~30%) in brain amyloid plaque load (quantified via histopathology), and significantly reduced levels of soluble and insoluble Aβ40 and Aβ42 amyloid species.

4.2 GABAergic Activity

Homotaurine and taurine are GABA mimetics evoking tonic GABA_AR currents in mouse cerebellar granule cells (CGC). GABA-dependent activity of tramiprosate has been reported. In rat primary neurons, tramiprosate binds with high affinity to the GABA-A receptors, inducing caspase 3/7 activation.

Homotaurine has >3-fold higher affinity for classical GABA_A-Rs and a longer half-life than GABA in plasma (approximately 3 hours vs. that of GABA). HT is a blood-brain barrier permeable drug under investigation for Alzheimer's disease. This blood-brain barrier permeability distinguishes homotaurine from GABA itself, which cannot cross the BBB. Oral GABA, which cannot cross the blood–brain barrier (BBB), does not affect the course of murine experimental autoimmune encephalomyelitis (EAE). In contrast, oral administration of the BBB-permeable GABA_A-R-specific agonist homotaurine ameliorates monophasic EAE, as well as advanced-stage relapsing–remitting EAE (RR-EAE).

100 μM HT (tramiprosate) inhibited neuronal death in cultures induced by 5 μM Aβ42. These findings suggest that taurine and HT can counteract possible direct excitotoxic effects of soluble Aβ through GABA_AR activation.

4.3 Anti-Inflammatory Activity

Mechanisms of action of tramiprosate include effects on amyloid, but also anti-inflammatory effects as demonstrated in MCI patients. Results from clinical research confirm that homotaurine treatment exerts an overall anti-inflammatory action in MCI patients, based not only on the down-regulation of pro-inflammatory IL-18, but also on up-regulation of the anti-inflammatory IL-33 and IL-10 cytokines, which in turn are associated with an amelioration of patients' cognitive functions.

HT also has beneficial effects in a mouse model of multiple sclerosis likely through an anti-inflammatory mechanism mediated by GABA_A receptor (GABA_AR) agonism in immune cells. Many different types of murine and human immune cells also express GABA-Rs. Human T cells also express GABA_A-Rs that can be modulated by GABA_A-R agonists and antagonists.

4.4 Tau-Related Activity

One preclinical study observed that tramiprosate (3-APS) favored tau polymerization in fibrillar aggregates, but these tau aggregates were not toxic in neuronal cultures. 3-APS also did not affect the binding of tau to microtubules and it promoted the decrease of tau-actin complexes that could be toxic for the cells.

4.5 Pharmacokinetics and Metabolic Considerations

Orally administered homotaurine undergoes extensive gastrointestinal metabolism, resulting in nausea, vomiting, and considerable pharmacokinetic variability. To address these issues, ALZ-801, a prodrug of homotaurine, was developed. ALZ-801 improves gastrointestinal tolerability and lowers oral pharmacokinetic variability while preserving homotaurine efficacy. ALZ-801 is a prodrug of homotaurine, a modified amino acid previously developed under the names tramiprosate and Alzhemed™. ALZ-801 is converted to homotaurine in vivo, but is more easily absorbed and lasts longer in the blood than tramiprosate.

5. Scientific Evidence by Area of Use

5.1 Alzheimer's Disease (AD)

Phase II Clinical Evidence

A phase 2 study of 58 patients reported a dose-dependent decrease in CSF Aβ42 over three months (up to 70% reduction from baseline in the 150 mg group). While this biomarker finding was notable, the subsequent Phase III development was designed to confirm clinical efficacy.

Phase III Clinical Evidence: The Alphase Study

The aim of the Alphase Study was to assess the clinical efficacy, safety, and disease-modification effects of tramiprosate (homotaurine, ALZHEMEDTM) in mild-to-moderate Alzheimer's disease. It was a double-blind, placebo-controlled, randomized trial conducted in 67 clinical centres across North America. Patients were aged ≥ 50 years, with mild-to-moderate AD (Mini-Mental State Examination score between 16 and 26) and on stable doses of cholinesterase inhibitors, alone or with memantine. The intervention was 78-week treatment with placebo, tramiprosate 100 mg, or tramiprosate 150 mg BID. The Alzheimer Disease Assessment Scale – cognitive subscale (ADAS-cog) and Clinical Dementia Rating – Sum of Boxes (CDR-SB) were assessed at baseline and every 13 weeks. Baseline and 78-week MRI hippocampus volume measurements were conducted in a subgroup of patients.

Homotaurine was investigated in a Phase III clinical trial as a potential treatment for Alzheimer's disease that did not show efficacy. There were no differences in CSF Aβ40 or total tau. There were no significant effects of homotaurine on cognitive (ADAS-Cog) and clinical (CDR-sb) measures compared to placebo.

Post-Hoc Analyses and APOE4 Subgroup Findings

Post-hoc analyses have shown positive and significant effects of homotaurine on secondary endpoints and subgroups of patients, including a reduction in hippocampal volume loss and lower decline in memory function in the overall cohort, as well as a reduction in global cognitive decline in APOE4 allele carriers, suggesting a disease-modifying effect.

Subgroup analyses of the two Phase 3 trials reported a gene-dose effect with tramiprosate, showing no cognitive effect in ApoE4 non-carriers, intermediate benefits in ApoE4 heterozygotes, and the greatest cognitive benefit in ApoE4 homozygotes. Patients on the higher dose of tramiprosate (150 mg BID) and with mild (vs. moderate) Alzheimer's disease responded better to the drug. In fact, cognition in mild Alzheimer's ApoE4 homozygotes stabilized with tramiprosate and was 40% better than placebo, which the authors claimed is clinically meaningful.

The main limitation of these efficacy analyses is that they are post-hoc subgroup analyses from the North American study that did not achieve its primary objectives. The sample size of the APOE4/4 dataset was also limited, especially in the Mild subgroups. Within the APOE4/4 homozygous patients, randomization was not stratified based on baseline severity and the three dose arms were not precisely comparable. Therefore, these findings require confirmation in prospectively defined studies in the APOE4/4 homozygous patients at the Mild AD stage.

In the Phase III AD clinical trial, homotaurine did not satisfy pre-fixed primary outcomes, failing to demonstrate changes in cognitive function compared to placebo, but this result is possibly confounded by high statistical variability of data and is paralleled by post hoc analyses in a subgroup of patients, revealing some protective effects on hippocampal volume loss. Although safe and well tolerated, homotaurine is not authorized as a new AD drug, but it is currently used as a nutraceutical for memory protection and its use in treatment of cognitive decline symptoms is still considered promising.

5.2 Mild Cognitive Impairment (MCI)

The elevation of both IL-10 and IL-33 is significantly associated with an improvement of episodic memory of treated MCI patients, as measured by the Delayed Verbal Ray Test. These results confirm that homotaurine treatment exerts an overall anti-inflammatory action in MCI patients, based not only on the down-regulation of pro-inflammatory IL-18, but also on up-regulation of the anti-inflammatory IL-33 and IL-10 cytokines, which in turn are associated with an amelioration of patients' cognitive functions.

Homotaurine is an aminosulfonate compound naturally found in red algae, which has been demonstrated to have neuroprotective effects in rats systemically administered with kainic acid or following ischemic stroke. As a possible therapeutic agent for AD treatment, homotaurine reduces Aβ levels in CSF of patients with mild-to-moderate disease, slows brain atrophy, and exerts positive effects on cognitive impairment.

Evidence from MCI populations is preliminary. Studies are small and exploratory in design, and no large-scale, pre-registered RCT has established efficacy specifically in an MCI population as of the most recent literature.

5.3 ALZ-801 (Valiltramiprosate) Prodrug: Phase 2 and Phase 3 Evidence

ALZ-801, a prodrug of homotaurine, was analyzed in a large-scale phase 3 study (APOLLOE4; NCT04770220) of individuals with early to mild AD. The double-blind study included individuals who are homozygous for the ε4 allele of the apolipoprotein (APOE) gene. This 78-week double-blind, placebo-controlled, two-arm trial randomized 325 homozygotes (162 to placebo, 163 to 265 mg BID), stratified by MCI (MMSE 27–30) or Mild AD (MMSE 22–26).

Nausea (mostly mild) was the most common adverse event; incidence of ARIA-E was the same as placebo. In the overall population, ADAS-Cog13 did not achieve significance, but the hippocampus showed significant 18% slowing of atrophy. The pre-specified Mild group showed trends to HV atrophy slowing that did not translate to clinical benefits. The pre-specified MCI group showed significant 28% HV atrophy slowing with meaningful cognitive and functional benefits and positive trends on several secondary clinical outcomes.

Overall safety was favorable with no increased ARIA. In the high-risk APOE4/4 population, this positive benefit-risk profile supports valiltramiprosate's potential as an oral disease-modifying treatment for APOE4/4 homozygotes with MCI.

According to a presentation at the 2024 AAIC, 64 participants completed a third year of extended treatment. At 2.5 years, participants continued to show a reduction in cortical thinning and stabilization on the RAVLT. The fourth and final year finished in July 2025.

In 2017, ALZ-801 received Fast Track designation from the US FDA. A Phase 3 randomized double-blind placebo-controlled study of valiltramiprosate (APOLLOE4 trial) in people with APOE4/4 and early Alzheimer's disease was completed in 2025.

5.4 Cerebral Amyloid Angiopathy (CAA)

Homotaurine interferes with the formation of plaques in blood vessels in the brain, that are associated with a condition called cerebral amyloid angiopathy. A Phase II trial involved 24 CAA patients with lobar cerebral haemorrhage who were randomized to receive three different daily doses of Cerebril (tramiprosate) for a period of 12 weeks. No safety concerns were reported based on the most frequently reported adverse events (nausea and vomiting). This remains a small Phase II feasibility study; no larger controlled trials specifically targeting CAA with homotaurine have been completed.

5.5 Multiple Sclerosis (Preclinical Evidence Only)

Oral GABA, which cannot cross the blood–brain barrier, does not affect the course of murine experimental autoimmune encephalomyelitis (EAE). In contrast, oral administration of the BBB-permeable GABA_A-R-specific agonist homotaurine ameliorates monophasic EAE, as well as advanced-stage relapsing–remitting EAE (RR-EAE). Homotaurine treatment beginning after the first peak of paralysis reduced the spreading of Th17 and Th1 responses from the priming immunogen to a new myelin T cell epitope within the CNS. Antigen-presenting cells (APC) isolated from homotaurine-treated mice displayed an attenuated ability to promote autoantigen-specific T cell proliferation.

Working with both monophasic and relapsing-remitting mouse models of EAE, oral administration of homotaurine was shown to (1) enhance CD8+CD122+PD-1+ and CD4+Foxp3+ Treg, but not Breg, responses, (2) inhibit autoreactive Th17 and Th1 responses, and (3) effectively ameliorate ongoing disease.

Evidence strength for MS: preclinical (animal model) only. The ability of homotaurine treatment to limit epitope spreading within the CNS, along with its safety record, makes it an excellent candidate to help treat MS and other inflammatory disorders of the CNS. No human clinical trials in MS have been reported as of the available literature.

5.6 Glaucoma and Retinal Neuroprotection

The literature has highlighted a potential role of amyloid in the development of retinal ganglion cell (RGC) apoptosis in experimental models of glaucoma, making homotaurine potentially useful as a treatment in glaucoma. A recent study showed that the fixed combination of citicoline and homotaurine exhibits potent neuroprotective activities through distinct molecular mechanisms, demonstrating a synergistic effect in cultured retinal cells of the two compounds in reducing the proapoptotic effects associated with exposure to both glutamate and high doses of glucose.

Clinical trials of fixed-dose combinations—such as citicoline + homotaurine ± vitamin E or PQQ—show additive improvements in RGC electrophysiology, visual function, contrast sensitivity, and quality of life without altering intraocular pressure. However, current evidence remains limited by small sample sizes, heterogeneous study designs, and a lack of long-term real-world data.

5.7 Alcohol Dependence: Acamprosate (N-Acetyl Homotaurine)

While homotaurine itself has not been specifically studied as a treatment for alcohol dependence, its N-acetylated derivative, acamprosate, is directly relevant as it is metabolically and structurally related. Acamprosate, or N-acetyl homotaurine, is an N-methyl-D-aspartate (NMDA) receptor modulator approved by the Food and Drug Administration (FDA) as a pharmacological treatment for alcohol dependence. The exact mechanism of action of acamprosate is still under investigation, but the drug appears to work by promoting a balance between the excitatory and inhibitory neurotransmitters, glutamate and GABA, respectively, and it may help individuals with alcohol dependence by reducing withdrawal-associated distress. Acamprosate has low bioavailability but an excellent tolerability and safety profile.

Acamprosate modulates NMDA receptor transmission and may have indirect effects on GABA_A receptor transmission. It is known to decrease brain glutamate and increase β-endorphins in rodents and man. Acamprosate (N-acetyl homotaurine) was approved by the FDA in 2004 to treat alcohol dependence.

5.8 Anticonvulsant Activity

Homotaurine has shown anticonvulsant activities, reduction in skeletal muscle tonus, and hypothermic activity. Historical neurological research documented that homotaurine (3-aminopropanesulfonic acid; 3-APS) protects from the convulsant and cytotoxic effect of systemically administered kainic acid (Fariello et al., Neurology, 1982). These findings are from early preclinical and animal studies; no controlled clinical trials in epilepsy using homotaurine have been identified in the current literature.

6. Body Systems and Health Areas of Association

• Central Nervous System / Neurology: Primary research focus. Mechanisms include anti-amyloid aggregation, GABA_AR agonism, neuroprotection against excitotoxicity, and cortical plasticity modulation. Investigated for Alzheimer's disease and MCI.
• Immune / Neuroimmunology: HT has beneficial effects in a mouse model of multiple sclerosis likely through an anti-inflammatory mechanism mediated by GABA_A receptor agonism in immune cells. This extends to the modulation of T-cell autoreactivity in preclinical CNS inflammatory disease models.
• Ophthalmology / Retinal Health: Investigated as a component of neuroprotective combination supplements for glaucoma and retinal ganglion cell preservation.
• Cardiovascular / Cerebrovascular: Investigated in cerebral amyloid angiopathy (CAA) at the Phase II level.
• Addiction / Neuropsychiatry (via acamprosate): The parent structural series is implicated in GABAergic and glutamatergic balance relevant to alcohol dependence withdrawal.

7. Dosage Forms and Dosages Reported in Studies

In clinical studies, doses of 100–150 mg twice per day have been tested. The Alphase Phase III trial specifically used: 78-week treatment with placebo, tramiprosate 100 mg or tramiprosate 150 mg BID.

For the prodrug ALZ-801 in the APOLLOE4 Phase 3 trial: the trial randomized 325 homozygotes (162 to placebo, 163 to 265 mg BID).

In the glaucoma/retinal neuroprotection context: a fixed combination of Citicoline 500 mg plus Homotaurine 50 mg (plus pyrroloquinoline quinone) has been studied for retinal ganglion cell function in glaucoma subjects. A crossover study on open-angle glaucoma utilized a compound of homotaurine (3-amino-1-propane sulphonic acid, tramiprosate) in combination with citicoline and vitamin E.

In the CAA Phase II trial, 24 CAA patients were randomized to receive three different daily doses of Cerebril (tramiprosate) for a period of 12 weeks. Precise dose levels for each arm of this trial are not specified in the available abstracts.

For in vitro mechanistic studies, 100 μM HT (tramiprosate) inhibited neuronal death in cultures induced by 5 μM Aβ42.

In the IL-33/IL-10 MCI study and the neurophysiological MCI studies, the exact homotaurine dosage used is not specified in the available publication summaries.

8. Safety Considerations

General Tolerability Profile

The most common side effects of tramiprosate are gastrointestinal in nature (nausea and vomiting) and can occur in up to 23% of patients on the drug (compared to 13% in placebo). However, they tend to be mild and moderate in nature. From a safety perspective, tramiprosate showed a favorable safety profile in APOE4/4 homozygotes. The most common gastrointestinal events of nausea and vomiting are most likely mediated by a direct, local gastrointestinal (GI) irritation effect of tramiprosate in some subjects.

Less Common Adverse Events Reported in Phase III

Syncope, pneumonia, and weight loss were more common in the drug group (occurring in 3.8%, 2.3%, and 15% of patients, respectively). ApoE4 homozygotes also had an increased incidence of depression (13% vs. 9% for placebo).

Absence of ARIA

A notable safety signal that has emerged with anti-amyloid antibody therapies is Amyloid-Related Imaging Abnormalities (ARIA). In the APOLLOE4 Phase 3 trial, nausea (mostly mild) was the most common adverse event; incidence of ARIA-E was the same as placebo. Tramiprosate had shown promising efficacy signals with favorable safety in approximately 1,300 APOE4 carriers with AD, with no observed ARIA-E.

Pregnancy and Lactation

There is no sufficient reliable scientific information available in the indexed literature to determine the safety of homotaurine during pregnancy or breastfeeding.

Pharmacokinetic Variability and the Rationale for ALZ-801

Orally administered homotaurine undergoes extensive gastrointestinal metabolism, resulting in nausea, vomiting, and considerable pharmacokinetic variability. This pharmacokinetic unpredictability was identified as a limiting factor in interpreting the Phase III trial results for tramiprosate itself. The prodrug ALZ-801 was developed specifically to address these limitations: ALZ-801 is a prodrug that has improved pharmacokinetics, gastrointestinal tolerability, and metabolic stability compared to homotaurine.

Drug Interactions

There is no information on potential drug interactions, although there was no exclusion criteria for patients taking other drugs in the phase 2 and 3 clinical trials. Patients in the Alphase study were on stable doses of cholinesterase inhibitors, alone or with memantine, without apparent evidence of significant interaction signals.

Regulatory Status

After the failure of phase 3 clinical trials, homotaurine began to be sold as a supplement called Vivimind; however, in 2011, the FDA refused to permit sales of Vivimind in the US because, while homotaurine is naturally found in seaweed, the homotaurine in Vivimind is made synthetically. It is not currently approved as a pharmaceutical drug in the United States or European Union for any indication. Although safe and well tolerated, homotaurine is not authorized as a new AD drug, but it is currently used as a nutraceutical for memory protection.

9. Evidence Strength Summary

• Alzheimer's Disease (overall population): Phase III trials failed to meet primary endpoints. Evidence for clinical benefit in the general AD population is negative. Post-hoc subgroup data in APOE4/4 homozygotes is hypothesis-generating but cannot be used to establish efficacy.
• Alzheimer's Disease (APOE4/4, MCI stage, ALZ-801): The completed APOLLOE4 Phase 3 trial provides the strongest available evidence to date, showing significant hippocampal volume preservation (28%) and cognitive/functional benefits in the pre-specified MCI subgroup. The overall primary endpoint (ADAS-Cog13) was not statistically significant across the combined mild AD + MCI population.
• MCI / Neuroinflammation: Preliminary clinical evidence from small studies showing anti-inflammatory cytokine modulation. Insufficient for efficacy claims.
• Multiple Sclerosis: Preclinical (mouse model) only; no human trials identified.
• Glaucoma: Early clinical evidence from small combination-product studies; limited by small sample sizes and study design heterogeneity.
• Cerebral Amyloid Angiopathy: Phase II safety study only (n=24); no controlled efficacy data.
• Acamprosate / Alcohol Dependence: Acamprosate (N-acetyl homotaurine) is FDA-approved, with substantial randomized trial evidence, though efficacy is moderate and mechanism remains under investigation.

References

• Aisen PS, Gauthier S, Ferris SH, et al. Tramiprosate in mild-to-moderate Alzheimer's disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Archives of Medical Science. PMC3258678.
• Gauthier S, Aisen PS, Ferris SH, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. ScienceDirect.
• Manzano S, et al. A Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders. Frontiers in Neurology. 2020.
• Meera P, Uusi-Oukari M, Lipshutz GS, Wallner M. GABAA receptors as plausible molecular targets and mediators for taurine and homotaurine actions. Frontiers in Pharmacology. 2023.
• Anti-inflammatory Effects of Homotaurine in Patients With Amnestic Mild Cognitive Impairment. PMC6230970.
• Toppi E, et al. IL-33 and IL-10 Serum Levels Increase in MCI Patients Following Homotaurine Treatment. Front Immunol 2022;13:813951. PMC9061963.
• Homotaurine Induces Measurable Changes of Short Latency Afferent Inhibition in a Group of Mild Cognitive Impairment Individuals. PMC4172065.
• Homotaurine limits the spreading of T cell autoreactivity within the CNS and ameliorates disease in a model of multiple sclerosis. PMC7940650.
• Tian J, Dang H, Wallner M, Olsen R, Kaufman DL. Homotaurine, a safe blood-brain barrier permeable GABAA-R-specific agonist, ameliorates disease in mouse models of multiple sclerosis. Scientific Reports. 2018.
• GABAA receptors as plausible molecular targets and mediators for taurine and homotaurine actions. PubMed 38155909.
• Tramiprosate (Alzhemed) for Alzheimer's disease. PMC6513583 (Cochrane-related review).
• APOLLOE4 Phase 3 study of oral ALZ-801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics. PMC11322500.
• Phase 3 Trial of Oral Anti-Amyloid Agent ALZ-801/Valiltramiprosate in APOE4/4 Homozygotes with Early Alzheimer's Disease. PMC11712804.
• Efficacy and Safety of Oral Valiltramiprosate in APOE4/4 Homozygotes with Early AD: Topline Results from the APOLLOE4 Phase 3 Trial. PMC12726020.
• ALZ-801 Therapeutic Overview. ALZFORUM.
• Homotaurine (tramiprosate) Cognitive Vitality Report. Alzheimer's Drug Discovery Foundation.
• Homotaurine (Tramiprosate) UPDATE. Alzheimer's Drug Discovery Foundation. October 2023.
• Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. Therapeutics and Clinical Risk Management.
• Safety and Efficacy of Acamprosate for the Treatment of Alcohol Dependence. PMC3565569.
• Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. British Journal of Clinical Pharmacology. 2014.
• FDA New Dietary Ingredient Notification: Homotaurine. April 27, 2009. Regulations.gov.
• Homotaurine Metabolized to 3-Sulfopropanoate in Cupriavidus necator H16. PMC2747907.
• Homotaurine. Wikipedia (for nomenclature cross-reference).
• Rossi GCM et al. Multicenter, Prospective, Randomized, Single Blind, Cross-Over Study on the Effect of a Fixed Combination of Citicoline 500 mg Plus Homotaurine 50 mg on Pattern Electroretinogram (PERG) in Patients With Open Angle Glaucoma. Frontiers in Medicine. 2022.
• Effects of Citicoline, Homotaurine, and Vitamin E on Contrast Sensitivity and Visual-Related Quality of Life in Patients with Primary Open-Angle Glaucoma. PMC7730471.
• Pharmacological Insights and Therapeutic Potential of Homotaurine in Neurological Disorders. European Alliance for Innovation. 2024.
• Abushakra S, et al. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. Journal of Prevention of Alzheimer's Disease. 2017.